IMO, this post from last night on Yahoo is worth repeating here for those interested in MOGN:
Re: Size doesn't matter!!!
by: osprey500 04/12/02 12:18 am
Msg: 22613 of 22613
Hernando, I would have to disagree completely with your viewpoint. You may be right that Wall Street or the media doesn't care about another chemo or 5-HT antagonist. However, the fact that these are mundane, if highly effective, types of drugs is what attracted me to MOGN.
The fact is that the clinical trial pathway and FDA pathway for these types of drugs is well established. One just follows the path and it usually works out.
The FDA is a highly risk adverse, conservative, insular bureaucracy. When they are confronted with new style drugs and technology where they don't have a 500 page manual and a file cabinet of similar cases THEY FREEZE UP. If you look at new age drug classes like radioactive MABS, antisense drugs, gene therapy, regenerative therapy, stem cells etc., they can take forever to get approved. When confronted by new technology, the FDA is extremely cautious and that translates into huge delays.
Just try to find some gene therapy companies or stem cell companies and look at their stock prices. Very low and not moving for a reason, their clinical development is stalled.
In the short term, MOGN's focus on conventional small molecule drugs may seem unexciting, in the end it will pay off for everyone.
You use the example of GNTA as something that MOGN lacks. The reality is that GNTA is a one-drug highly risky company, the stock goes up and down in random ways like a yo-yo, and they will be either rich or dead. Probability of either one is unknown to me, 50-50 is a wild guess. Only my analysis, be well.
Posted as a reply to: Msg 22612 by hernando_de_soto |
